Research programme: glycoconjugate vaccines - LimmaTech Biologics
Alternative Names: Staphylococcus aureus vaccine - GlycoVaxyn; Glycoconjugate vaccines - GlycoVaxyn; Group A Streptococcus conjugate vaccine - GlycoVaxyn; Group B meningococcal vaccine - GlycoVaxyn; Uropathogenic E.Coli vaccine - GlycoVaxynLatest Information Update: 28 Aug 2018
At a glance
- Originator GlycoVaxyn
- Developer LimmaTech Biologics
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Staphylococcal infections
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Bacterial-infections in Switzerland (Parenteral)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Staphylococcal-infections in Switzerland (Parenteral)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (Parenteral)